Amprion, Inc. Receives Significant ALS Research Grant
Collaborative effort aimed at improving treatment options for sporadic ALS
The ALS Network has taken a considerable step forward in the fight against amyotrophic lateral sclerosis (ALS) by granting Amprion, Inc. a substantial $100,000. This funding will enhance Amprion's work in diagnosing and developing treatments for sporadic ALS, a difficult form of the disease that impacts countless people around the globe.
What is Sporadic ALS?
ALS is a deadly neurodegenerative disease that attacks nerve cells in both the brain and spinal cord, leading to a gradual loss of muscle control. Those diagnosed with ALS suffer from severe symptoms that severely limit their ability to move, speak, swallow, and breathe. It's worth noting that veterans are diagnosed with ALS nearly twice as often as the general population.
Amprion's Role in ALS Research
Located in San Diego, Amprion is pioneering research to understand the causes of sporadic ALS. The company employs innovative seed amplification testing, also referred to as the Seed Amplification Assay (SAA), to detect misfolded proteins thought to play a significant role in the disease's development. Their focus is on identifying specific biomarkers, which could lead to more personalized therapies for patients.
Collaborative Research and New Findings
This grant, led by Dr. Richard Smith and Dr. Russ Liebovitz, will enable collaboration among some of the top scientists and doctors dedicated to unraveling the complexities of ALS pathology. A recent study they published in a respected journal discovered that around 15% of patients with sporadic ALS showed Lewy Body co-pathology, revealing an important aspect of the disease's intricate nature.
Potential Treatment Options
Dr. Liebovitz expressed hope regarding their findings, mentioning that misfolded alpha-synuclein in certain ALS patients may be linked to distinct clinical features, such as faster symptom progression and cognitive decline. The grant is aimed at funding additional studies that could lead to a treatment strategy specifically for this variant of ALS.
Expanding Research Goals
Amprion's research objectives go beyond just alpha-synuclein, as the company aims to develop lab tests that will identify other misfolded proteins related to ALS. This broadened focus will involve neurologists assessing whether various misfolded proteins yield different clinical symptoms in ALS patients.
The ALS Network's Commitment
The ALS Network's dedication to supporting impactful research is evident through its rigorous selection process, managed by its Scientific Advisory Committee. This committee is made up of esteemed researchers and healthcare professionals who thoroughly evaluate and fund promising ALS research projects.
Sheri Strahl, the president and CEO of the ALS Network, emphasized the importance of advancing science in the field of ALS. She pointed out that it’s both a challenge and a necessity, aiming to speed up groundbreaking research that prioritizes improving patient care and outcomes. Strahl noted that Amprion's efforts are critical to accelerating the search for therapies for ALS and other neurodegenerative disorders.
Contact Information
If you want more details about this initiative or are interested in discussing potential collaborations, please reach out to:
Vanessa Martin
310-560-4726
Eric Beikmann
310-560-4726
Frequently Asked Questions
What is the purpose of the grant awarded to Amprion?
The grant is meant to support research into therapies for sporadic ALS, particularly focusing on the impact of misfolded proteins in the progression of the disease.
Who is leading the research project at Amprion?
Dr. Richard Smith and Dr. Russ Liebovitz are spearheading the research project aimed at understanding the complexities of sporadic ALS.
What key findings came from the recent study?
The study revealed that around 15% of patients with sporadic ALS showed signs of Lewy Body co-pathology, suggesting a possible connection between these misfolded proteins and ALS symptoms.
How does Amprion's research approach differ from others?
Amprion utilizes advanced testing techniques, specifically the Seed Amplification Assay, to identify and analyze the role of misfolded proteins in ALS.
How can organizations partner with the ALS Network?
Organizations interested in collaborating with the ALS Network can directly contact them to explore partnership opportunities in ALS research initiatives.
